Key result
SGLT2 inhibitor initiation in 13 HFpEF/HFmrEF patients with an implanted PAP sensor did not change cardiopulmonary hemodynamics over 9 months.
Why the study?
Although SGLT2 inhibitors reduce PAP in NYHA class III HF with a PAP sensor, their impact on PVR, PCWP, PAC, and RV-PA coupling in HFpEF/HFmrEF, and whether PVR and PCWP can be calculated non-invasively, was unclear.
Does SGLT2 inhibitor initiation improve cardiopulmonary hemodynamics in HFpEF/HFmrEF patients with an implanted PAP sensor?
Observational (n=13)
Does SGLT2 inhibitor initiation improve cardiopulmonary hemodynamics in HFpEF/HFmrEF patients with an implanted PAP sensor?
In a small pilot study of HFpEF/HFmrEF patients with implanted PAP sensors, SGLT2 inhibitor initiation did not significantly change cardiopulmonary hemodynamics over 9 months.
Answers are grounded in this paper and cite their sources.
This small series does not support routine PAP monitoring to gauge SGLT2i response in HFpEF; leaves open effects in larger prospective trials.
The initiation of sodium–glucose cotransporter 2 (SGLT2) inhibitor treatment was shown to reduce pulmonary artery pressure (PAP) in New York Heart Association (NYHA) class III heart failure (HF) patients with an implanted PAP sensor. We aimed to investigate the impact of SGLT2-I initiation on pulmonary vascular resistance (PVR), pulmonary capillary wedge pressure (PCWP), pulmonary arterial capacitance (PAC), and right ventricle (RV) to PA (RV-PA) coupling in a pilot cohort of HF with preserved/mildly reduced ejection fraction (HFpEF/HFmrEF) patients and whether PVR and PCWP can be serially calculated non-invasively using PAP sensor data during follow-up. Methods: Right heart catheterization parameters (PVR, PCWP, and PAC) were obtained at sensor implantation and echocardiographic assessments (E/E’, RV-PA coupling, and RV cardiac output) were made at baseline and every 3 months. SGLT2 inhibition was initiated after 3 months of telemedical care. Three methods for calculating PVR and PCWP were compared using Bland–Altman plots and Spearman’s correlation. Results: In 13 HF patients (mean age 77 ± 4 years), there were no significant changes in PAP, PVR, PCWP, RV-PA coupling, or PAC over 9 months (all p-values > 0.05), including after SGLT2-I initiation. PVR values were closely correlated across the three methods (PVRNew and PVRNew Tedford (r = 0.614, p < 0.001), PVREcho and PVRNew Tedford (r = 0.446, p = 0.006), and PVREcho and PVRNew (r = 0.394, p = 0.016)), but PCWP methods lacked reliable association (PCWPEcho and PCWPNew (r = 0.180, p = 0.332). Conclusions: No changes in cardiopulmonary hemodynamics were detected after hemodynamic telemonitoring either prior to or following SGLT2-I initiation. Different PVR assessment methods yielded comparable results, whereas PCWP methods were not associated with each other. Further investigations with larger cohorts including repeated right heart catheterization are planned.
No takes yet. Share an insight, caveat, or question.
Herrmann et al. (2025) conducted an observational in HFpEF/HFmrEF (n=13). SGLT2 inhibitor was evaluated on Changes in PAP, PVR, PCWP, RV-PA coupling, or PAC (p=>0.05). SGLT2 inhibitor initiation in 13 HFpEF/HFmrEF patients with an implanted PAP sensor did not change cardiopulmonary hemodynamics over 9 months.
Synapse has enriched 10 related papers. Consider them for comparative context: